JP2023541379A5 - - Google Patents
Info
- Publication number
- JP2023541379A5 JP2023541379A5 JP2023513936A JP2023513936A JP2023541379A5 JP 2023541379 A5 JP2023541379 A5 JP 2023541379A5 JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023541379 A5 JP2023541379 A5 JP 2023541379A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- less
- dose
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073353P | 2020-09-01 | 2020-09-01 | |
| US63/073,353 | 2020-09-01 | ||
| US202163212077P | 2021-06-17 | 2021-06-17 | |
| US63/212,077 | 2021-06-17 | ||
| PCT/US2021/048540 WO2022051305A1 (en) | 2020-09-01 | 2021-08-31 | Compositions and methods for improving neurological diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541379A JP2023541379A (ja) | 2023-10-02 |
| JP2023541379A5 true JP2023541379A5 (enExample) | 2024-09-09 |
Family
ID=80491939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513936A Pending JP2023541379A (ja) | 2020-09-01 | 2021-08-31 | 神経系の疾患及び障害を改善するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263749A1 (enExample) |
| EP (1) | EP4208159A4 (enExample) |
| JP (1) | JP2023541379A (enExample) |
| KR (1) | KR20230107211A (enExample) |
| CN (1) | CN116801875B (enExample) |
| AU (1) | AU2021337583A1 (enExample) |
| CA (1) | CA3189243A1 (enExample) |
| MX (1) | MX2023002350A (enExample) |
| WO (1) | WO2022051305A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022185255A1 (en) | 2021-03-03 | 2022-09-09 | Lenovo (Singapore) Pte. Ltd. | Beam failure detection using multiple sets of reference signals |
| US20260207568A1 (en) * | 2022-12-21 | 2026-07-23 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| US20250107713A1 (en) * | 2023-09-29 | 2025-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Confirming Iboga Alkaloid Treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952101A (en) * | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2002032897A1 (en) * | 2000-10-20 | 2002-04-25 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| WO2018195473A1 (en) * | 2017-04-20 | 2018-10-25 | The Brigham And Women's Hospital, Inc. | Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| AU2019287771A1 (en) * | 2018-06-14 | 2021-01-28 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| US10947196B2 (en) * | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| US20220401415A1 (en) * | 2019-10-25 | 2022-12-22 | Curasen Therapeutics, Inc. | Methods for treating neurological disorders with alpha1a-ar partial agonists |
| US11607395B2 (en) * | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
-
2021
- 2021-08-31 JP JP2023513936A patent/JP2023541379A/ja active Pending
- 2021-08-31 KR KR1020237010888A patent/KR20230107211A/ko active Pending
- 2021-08-31 WO PCT/US2021/048540 patent/WO2022051305A1/en not_active Ceased
- 2021-08-31 CA CA3189243A patent/CA3189243A1/en active Pending
- 2021-08-31 CN CN202180068273.8A patent/CN116801875B/zh active Active
- 2021-08-31 EP EP21865003.4A patent/EP4208159A4/en active Pending
- 2021-08-31 US US18/023,693 patent/US20230263749A1/en not_active Abandoned
- 2021-08-31 AU AU2021337583A patent/AU2021337583A1/en active Pending
- 2021-08-31 MX MX2023002350A patent/MX2023002350A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507408A5 (enExample) | ||
| JP4637351B2 (ja) | 神経変性疾患の処置法 | |
| JP6517827B2 (ja) | イソインドリン組成物および神経変性疾患の治療方法 | |
| JP2021527712A5 (enExample) | ||
| DE69936335T2 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| KR101581289B1 (ko) | 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민 | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2008520589A5 (enExample) | ||
| JP2004515477A (ja) | Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法 | |
| RU2007119585A (ru) | Производные рапамицина и их применение при лечении неврологических заболеваний | |
| AU2020206826B2 (en) | Ketamine pamoate and use thereof | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2017508736A (ja) | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 | |
| JP2025032222A (ja) | Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法 | |
| JP2023525359A (ja) | Ｓａｒｓの治療のための化合物 | |
| JP2023541379A (ja) | 神経系の疾患及び障害を改善するための組成物及び方法 | |
| CN1819822A (zh) | 含有取代喹啉和取代二苯砜的组合物以及使用方法 | |
| CN114539128B (zh) | 用于检测β-淀粉样蛋白的水溶性化合物 | |
| JPH0466477B2 (enExample) | ||
| JP2021512958A (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| PT1551412E (pt) | COMPOSIÇÕES FARMACjUTICAS PARA O TRATAMENTO DE DOENÇAS ASSOCIADAS ÀS NEUROTROFINAS | |
| CN111566084B (zh) | 中枢神经系统疾病的新疗法 | |
| JPH08512305A (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| CN111617255B (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| EP4582412A1 (en) | Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor |